Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2392103A (GSK)
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2392103A is an investigational 4-component biological vaccine developed by GSK for the prevention of *Staphylococcus aureus* infections. The vaccine consists of four antigens: alpha-toxin (Hla), clumping factor A (ClfA), and capsular polysaccharides CP5 and CP8, which are conjugated to a tetanus toxoid carrier protein. It is formulated with the AS03B adjuvant, an oil-in-water emulsion. The vaccine was designed to elicit both humoral and cellular immune responses against key virulence factors of *S. aureus*. Development reached Phase 1 clinical testing (NCT01160172) in healthy adults to assess safety and immunogenicity, but the program was discontinued following the completion of the trial in 2012.
- Other names
- GSK Staphylococcal 4-component vaccine
02
Targets
CP5 (Staphylococcus aureus capsular polysaccharide type 5)Hla (Staphylococcus aureus alpha toxin)ClfA (Clumping factor A)CP8 (Staphylococcus aureus capsular polysaccharide type 8)TT (Tetanus toxoid)
Beyond the preview
Go deeper on GSK2392103A (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2392103A (GSK).